Sanofi Stock Price, News & Analysis (EPA:SAN)

€73.55 -0.22 (-0.30 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close€73.55
Today's Range€72.79 - €73.78
52-Week Range€72.63 - €92.97
Volume4.38 million shs
Average Volume2.31 million shs
Market Capitalization$92.90 billion
P/E RatioN/A
Dividend Yield4.02%
BetaN/A

About Sanofi (EPA:SAN)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorHealthcare
SymbolEPA:SAN
CUSIPN/A
Phone+33-1-53774000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS€3.61
Net IncomeN/A
Net Margins15.85%
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares1,260,000,000

Sanofi (EPA:SAN) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

14 Wall Street analysts have issued 12 month price objectives for Sanofi's shares. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi's stock price to reach €88.79 in the next twelve months. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)
  • Alan J. Main Ph.D., Executive Vice President, Consumer Healthcare; Member of the Executive Committee (Age 63)

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately €73.55.

How big of a company is Sanofi?

Sanofi has a market capitalization of $92.90 billion.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.


MarketBeat Community Rating for Sanofi (SAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  454 (Vote Underperform)
Total Votes:  822
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (EPA:SAN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.252.242.242.24
Ratings Breakdown: 1 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €87.50€86.94€87.31€86.81

Sanofi (EPA:SAN) Consensus Price Target History

Price Target History for Sanofi (EPA:SAN)

Sanofi (EPA:SAN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/3/2017S&P GlobalSet Price TargetNeutral€83.00View Rating Details
11/3/2017Goldman Sachs GroupSet Price TargetNeutral€82.00View Rating Details
11/2/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
11/2/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
10/26/2017Morgan StanleySet Price TargetBuy€92.00View Rating Details
10/18/2017Deutsche BankSet Price TargetBuy€96.00View Rating Details
10/16/2017Jefferies GroupSet Price TargetNeutral€90.00View Rating Details
10/6/2017CitigroupSet Price TargetNeutral€88.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
9/7/2017Kepler Capital MarketsSet Price TargetBuy€90.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
5/8/2017BarclaysSet Price TargetSell€75.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
12/6/2016S&P GlobalSet Price TargetNeutral€80.00View Rating Details
6/30/2016Independent ResearchSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 12/17/2015 forward)

Earnings

Earnings History for Sanofi (EPA:SAN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Sanofi (EPA:SAN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi (EPA:SAN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi (EPA SAN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Sanofi (EPA SAN) News Headlines

Source:
DateHeadline
Mylan Announces IPR Proceedings for Sanofis Lantus Patents ... - NasdaqMylan Announces IPR Proceedings for Sanofi's Lantus Patents ... - Nasdaq
www.nasdaq.com - December 16 at 5:36 AM
Sanofi: FDA lifts clinical hold on fitusiran - GlobeNewswire (press release)Sanofi: FDA lifts clinical hold on fitusiran - GlobeNewswire (press release)
globenewswire.com - December 15 at 3:16 PM
Alnylam Gets Some Welcome NewsAlnylam Gets Some Welcome News
finance.yahoo.com - December 15 at 3:16 PM
Sanofi: FDA lifts clinical hold on fitusiranSanofi: FDA lifts clinical hold on fitusiran
feeds.benzinga.com - December 15 at 7:55 AM
Sanofi Wants to Go It Alone -- Good Luck With That - BloombergSanofi Wants to Go It Alone -- Good Luck With That - Bloomberg
www.bloomberg.com - December 14 at 3:16 PM
Sanofi Wants to Go It Alone -- Good Luck With ThatSanofi Wants to Go It Alone -- Good Luck With That
finance.yahoo.com - December 14 at 3:16 PM
Sanofis planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4% - Seeking AlphaSanofi's planned marketing application for diabetes med propels licensor Lexicon Pharmaceuticals, up 4% - Seeking Alpha
seekingalpha.com - December 14 at 5:33 AM
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
finance.yahoo.com - December 14 at 5:33 AM
Sanofi expects to file nine regulatory submissions over next 18 months - Seeking AlphaSanofi expects to file nine regulatory submissions over next 18 months - Seeking Alpha
seekingalpha.com - December 13 at 3:17 PM
Sanofi looks to pipeline after setbacks - Financial TimesSanofi looks to pipeline after setbacks - Financial Times
www.ft.com - December 13 at 3:17 PM
Top 10 Generic Pharmaceutical Companies In 2017Top 10 Generic Pharmaceutical Companies In 2017
finance.yahoo.com - December 13 at 3:17 PM
Did Sanofi, WHO ignore warning signals on dengue vaccine? - ReutersDid Sanofi, WHO ignore warning signals on dengue vaccine? - Reuters
www.reuters.com - December 13 at 5:32 AM
Sanofi : Sanofi presents R&D strategy and innovative pipeline - GlobeNewswire (press release)Sanofi : Sanofi presents R&D strategy and innovative pipeline - GlobeNewswire (press release)
globenewswire.com - December 13 at 5:32 AM
Sanofi sees nine regulatory submissions over next 18 monthsSanofi sees nine regulatory submissions over next 18 months
finance.yahoo.com - December 13 at 5:32 AM
Sanofi : Sanofi presents R&D strategy and innovative pipelineSanofi : Sanofi presents R&D strategy and innovative pipeline
finance.yahoo.com - December 13 at 5:32 AM
Frances Sanofi pins hopes on new drugs after setbacksFrance's Sanofi pins hopes on new drugs after setbacks
finance.yahoo.com - December 13 at 5:32 AM
Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell CarcinomaRegeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
www.prnewswire.com - December 13 at 2:48 AM
Regeneron Collaboration Programs Highlighted During Sanofi Analyst DayRegeneron Collaboration Programs Highlighted During Sanofi Analyst Day
www.prnewswire.com - December 13 at 2:48 AM
Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinomaSanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
feeds.benzinga.com - December 13 at 2:48 AM
Sanofi  : Sanofi presents R&D strategy and innovative pipelineSanofi : Sanofi presents R&D strategy and innovative pipeline
feeds.benzinga.com - December 13 at 2:48 AM
Sanofi gets FDA OK for insulin injection AdmelogSanofi gets FDA OK for insulin injection Admelog
www.marketwatch.com - December 12 at 3:15 PM
Sanofi investors hungry for drug progress and deal newsSanofi investors hungry for drug progress and deal news
www.reuters.com - December 12 at 3:15 PM
Dengue Fever Vaccine Suspension Criticized by Drugmaker SanofiDengue Fever Vaccine Suspension Criticized by Drugmaker Sanofi
finance.yahoo.com - December 12 at 3:15 PM
The results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®s valueThe results of a recent study favour Toujeo® over degludec and real-world evidence confirms Toujeo®'s value
finance.yahoo.com - December 12 at 3:15 PM
FDA approves Sanofis rapid-acting insulin analog Admelog; shares up 1% - Seeking AlphaFDA approves Sanofi's rapid-acting insulin analog Admelog; shares up 1% - Seeking Alpha
seekingalpha.com - December 12 at 5:49 AM
Sanofi scandal in the Philippines could spread dangerous mistrust of vaccinesSanofi scandal in the Philippines could spread dangerous mistrust of vaccines
www.msn.com - December 11 at 3:15 PM
FDA OKs Sanofis follow-on biologic of Lillys diabetes drug HumalogFDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog
www.reuters.com - December 11 at 3:15 PM
FDA Approves Sanofis Admelog® (insulin lispro injection) - GlobeNewswire (press release)FDA Approves Sanofi's Admelog® (insulin lispro injection) - GlobeNewswire (press release)
globenewswire.com - December 11 at 3:15 PM
FDA Approves Sanofis Admelog® (insulin lispro injection)FDA Approves Sanofi's Admelog® (insulin lispro injection)
feeds.benzinga.com - December 11 at 2:52 PM
Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 5:44 AM
Sanofi Genzyme recalls arthritis medicine following surge in side effectsSanofi Genzyme recalls arthritis medicine following surge in side effects
www.msn.com - December 9 at 3:16 PM
Philippines to seek refund of $59 million from Sanofi amid vaccine risk - ReutersPhilippines to seek refund of $59 million from Sanofi amid vaccine risk - Reuters
www.reuters.com - December 9 at 3:16 PM
Sanofi Begins Combo Studies on Multiple Myeloma Candidate - NasdaqSanofi Begins Combo Studies on Multiple Myeloma Candidate - Nasdaq
www.nasdaq.com - December 9 at 5:26 AM
Sanofi signs deal to produce vaccines in AlgeriaSanofi signs deal to produce vaccines in Algeria
www.marketwatch.com - December 8 at 3:15 PM
Sanofi Begins Combo Studies on Multiple Myeloma CandidateSanofi Begins Combo Studies on Multiple Myeloma Candidate
finance.yahoo.com - December 8 at 3:15 PM
Sanofi (SNY) a Hold on Vapid Earnings MomentumSanofi (SNY) a Hold on Vapid Earnings Momentum
investorplace.com - December 8 at 10:54 AM
Philippines wants money back from Sanofi for dengue vaccine - ABC NewsPhilippines wants money back from Sanofi for dengue vaccine - ABC News
abcnews.go.com - December 8 at 5:41 AM
Sanofi explores combination treatments for multiple myeloma in new late-stage trials - Business Wire (press release)Sanofi explores combination treatments for multiple myeloma in new late-stage trials - Business Wire (press release)
www.businesswire.com - December 8 at 5:41 AM
Philippines to seek refund of $59 million from Sanofi amid vaccine riskPhilippines to seek refund of $59 million from Sanofi amid vaccine risk
finance.yahoo.com - December 8 at 5:41 AM
Philippines threatens Sanofi with legal action over dengue vaccinePhilippines threatens Sanofi with legal action over dengue vaccine
www.ft.com - December 7 at 3:16 PM
Sanofis Pointeau on China Strategy, PartnershipsSanofi's Pointeau on China Strategy, Partnerships
finance.yahoo.com - December 7 at 3:16 PM
Sanofi (SAN) Receives Average Rating of "Hold" from AnalystsSanofi (SAN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - December 7 at 8:34 AM
Flu cases double as experts worry this season could be particularly badFlu cases double as experts worry this season could be particularly bad
finance.yahoo.com - December 6 at 3:15 PM
Brazil recommends restrictions on Sanofi dengue vaccine - Reuters - ReutersBrazil recommends restrictions on Sanofi dengue vaccine - Reuters - Reuters
www.reuters.com - December 6 at 5:36 AM
Philippines halts sale of dengue vaccine as Sanofi downplays riskPhilippines halts sale of dengue vaccine as Sanofi downplays risk
www.reuters.com - December 5 at 3:15 PM
France advised against Sanofis dengue drug for its territoriesFrance advised against Sanofi's dengue drug for its territories
finance.yahoo.com - December 5 at 3:15 PM
WHO reviewing data on Sanofi dengue vaccine, urges limited use - ReutersWHO reviewing data on Sanofi dengue vaccine, urges limited use - Reuters
www.reuters.com - December 5 at 5:46 AM
Trial results of Zika vaccine Sanofi dropped show promise - ReutersTrial results of Zika vaccine Sanofi dropped show promise - Reuters
www.reuters.com - December 5 at 5:46 AM
Brainstorm Health: CVS Aetna Takeaways, Prescription Videogames, Sanofi Dengue Vaccine ProbeBrainstorm Health: CVS Aetna Takeaways, Prescription Videogames, Sanofi Dengue Vaccine Probe
fortune.com - December 4 at 3:15 PM
Sanofi says monitoring outcomes of ongoing dengue vaccination schemesSanofi says monitoring outcomes of ongoing dengue vaccination schemes
www.reuters.com - December 4 at 3:15 PM

SEC Filings

Sanofi (EPA:SAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Sanofi (EPA SAN) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.